Open Label, Dose Escalation Study of Paricalcitol (Zempla) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies.

Trial Profile

Open Label, Dose Escalation Study of Paricalcitol (Zempla) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2014

At a glance

  • Drugs Paricalcitol (Primary) ; Gemcitabine
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 May 2012 Planned End Date changed from 1 Apr 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top